Perioperative anemia is very common in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA). This study retrospectively analyzes the use of rHuEPO and iron sucrose in patients undergoing total hip and knee arthroplasty in order to observe the short-term efficacy and safety of rHuEPO and iron sucrose.
This study aims to explore whether short-term use of rHuEPO and iron sucrose can improve postoperative anemia and promote postoperative rehabilitation after hip and knee arthroplasty. According to different therapies of perioperative anemia , included subjects would be divided into rHuEPO monotherapy group, iron sucrose monotherapy group, rHuEPO combined with iron sucrose group and control group (without rHuEPO and iron sucrose).
Study Type
OBSERVATIONAL
Enrollment
780
rHuEPO was administrated daily with 10000 IU or 20000 IU
Iron sucrose was administrated daily with 100mg or 200mg
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGDifferences in changes of Hb level in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
Changes of Hb level =Hb level in postoperative 7d - Hb level in operation day
Time frame: Operation day to postoperative day 7
Differences in change of red blood cells count(RBC) in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
Changes of RBC =RBC in postoperative day 7 - RBC in operation day
Time frame: Operation day to postoperative day 7
Differences in change of hematokrit (HCT) in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
Changes of HCT =HCT level in postoperative day 7 - HCT level in operation day
Time frame: Operation day to postoperative day 7
Differences in change of allogeneic transfusion rate(%) in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
Transfusion rate is defined as the ratio of numbers subjected to blood transfusion in each group subjects. Blood transfusion volume is defined as the amount of blood transfusion during operation day and postoperative period.
Time frame: Operation day to postoperative day 7
Differences in change of allogeneic blood transfusion volume in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
Allogeneic blood transfusion volume is defined as the amount of blood transfusion volume from operation day to postoperative day 7 Blood transfusion volume is defined as the amount of blood transfusion during operation day and postoperative period.
Time frame: Operation day to postoperative day 7
Difference in postoperative hospital days in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Postoperative hospital days is defined as the number of days from operation day to hospital discharge.
Time frame: Up to 4 months
Comparing differences of blood loss volume in each group.
Blood loss volume is defined as the total volume of intraoperative bleeding and postoperative drainage.
Time frame: Operation day to postoperative day 7
Comparing the rate of anemia between operation day and post-operation day 7 in each group.
According to 2011 World Health Organization(WHO) anemia standard，Hb\< 130g/L for adult men and Hb \< 120g/L for non-pregnant women are defined as anemia.
Time frame: Operation day to postoperation day 7
Differences in changes of platelet count in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group.
Changes of platelet count =platelet count in postoperative 7d - platelet count in operation day
Time frame: Operation day to postoperative day 7
Safety of rHuEPO and/or iron sucrose
Adverse events and serious adverse events
Time frame: Form operation day to postoperative day 7